BRAF and melanoma: We now also show that the clinically applied combination of BRAF/MEK inhibition does not compromise the therapeutic effects of intratumoral RIG-I activation in in vivo melanoma models: first, 3pRNA directly acts within the tumor cells, likely inducing a caspase-dependent cell death as observed previously,23 thereby reducing tumor burden.